伐米胺 | 97987-88-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 伐米胺
• 中文别名: L-鸟氨酸7-酰氨基-4-甲基香豆素,碳酸酯盐
• 英文名称: 4-(dimethylamino)-2-phenyl-2-(2-pyridyl)pentanamide
• 英文别名: (2R*,4R*)-4-dimethylamino-2-phenyl-2-(pyridin-2-yl)-valeramide；4-(N,N-dimethylamino)-2-phenyl-2-(pyridin-2-yl)-valeramide；4-(N,N-dimethylamino)-2-phenyl-2-(2-pyridyl)-valeramide；(+/-)-(2R*,4R*)-4-dimethylamino-2-phenyl-2-(2-pyridyl)-valeramide；4-(dimethylamino)-2-phenyl-2-pyridin-2-ylpentanamide
• CAS: 97987-88-7
• 化学式: C₁₈H₂₃N₃O
• 分子量: 297.4
• InChiKey: BWNLUIXQIHPUGO-UHFFFAOYSA-N

物化性质

• 沸点：
  477.6±45.0 °C(Predicted)
• 密度：
  1.099±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  59.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  伐米胺 生成 (+)-(2S,4S)-4-(dimethylamino)-2-phenyl-2-(2-pyridyl)pentanamide
  参考文献：
  名称：

  Synthesis and Anticholinergic Activity of the Four Stereoisomers of 4-(Dimethylamino)-2-phenyl-2-(2-pyridyl)pentanamide

  摘要：

  The four stereoisomers of 4-(dimethylamino)-2-phenyl-(2-pyridyl)pentanamide were synthesized, and the absolute configurations were determined by X-ray crystallography. Pharmacological testing for anticholinergic activity revealed great differences in potency among 10 (2R,4R, IC50 = 0.40 mu M), 11 (2S,4S, 31 mu M), 12 (2R,4S, 170 mu M), and 13 (2S,4R, 0.13 mu M). A new drug application for the racemate 8 (FK176, vamicamide) has been filed in Japan for the treatment of overactive detrusor syndrome.

  DOI：

  10.1021/jm00035a019
• 作为产物：
  描述：

  苯基吡啶-2-乙腈 在 氢氧化钾 、 sodium tetrahydroborate 、 硫酸 、 四氯化钛 作用下， 以 溶剂黄146 为溶剂， 反应 6.17h， 生成 伐米胺
  参考文献：
  名称：

  Synthesis and Anticholinergic Activity of the Four Stereoisomers of 4-(Dimethylamino)-2-phenyl-2-(2-pyridyl)pentanamide

  摘要：

  The four stereoisomers of 4-(dimethylamino)-2-phenyl-(2-pyridyl)pentanamide were synthesized, and the absolute configurations were determined by X-ray crystallography. Pharmacological testing for anticholinergic activity revealed great differences in potency among 10 (2R,4R, IC50 = 0.40 mu M), 11 (2S,4S, 31 mu M), 12 (2R,4S, 170 mu M), and 13 (2S,4R, 0.13 mu M). A new drug application for the racemate 8 (FK176, vamicamide) has been filed in Japan for the treatment of overactive detrusor syndrome.

  DOI：

  10.1021/jm00035a019

文献信息

• .alpha.-Aryl-.alpha.-pyridylalkanoic acid derivatives, process for
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04564621A1

  公开（公告）日：1986-01-14

  New .alpha.-aryl-.alpha.-pyridylalkanoic acid derivatives of the formula: ##STR1## wherein R.sup.1 is cyano or carbamoyl, R.sup.2 is hydrogen or halogen, R.sup.3 is hydrogen or lower alkyl, one of R.sup.4 and R.sup.5 is hydrogen and another is lower alkyl, R.sup.6 is hydrogen or lower alkyl, and R.sup.7 is lower alkyl, or R.sup.6 and R.sup.7 are taken together to form an N-containing saturated heterocyclic group with the adjacent nitrogen atom, in which the heterocyclic group may be substituted with lower alkyl or optionally protected hydroxy(lower)alkyl, provided that R.sup.2 is halogen or R.sup.3 is lower alkyl, when R.sup.1 is cyano and R.sup.6 and R.sup.7 are each lower alkyl, and salts thereof, and processes for preparation thereof and pharmaceutical composition comprising the same. These derivatives and salts thereof are useful as antiulcer agents and spasmolytic agents.

  新的.alpha.-芳基-.alpha.-吡啶基脂肪酸衍生物的化学式为：##STR1## 其中R.sup.1是氰基或氨基甲酰基，R.sup.2是氢或卤素，R.sup.3是氢或较低的烷基，R.sup.4和R.sup.5中的一个是氢，另一个是较低的烷基，R.sup.6是氢或较低的烷基，而R.sup.7是较低的烷基，或者R.sup.6和R.sup.7在一起形成一个含氮饱和杂环基团，与相邻的氮原子一起，其中杂环基团可以用较低的烷基或可选择的保护羟基（较低）烷基取代，前提是当R.sup.1为氰基且R.sup.6和R.sup.7分别为较低的烷基时，R.sup.2为卤素或R.sup.3为较低的烷基，以及其盐，以及制备它们的过程和包含它们的药物组合物。这些衍生物及其盐可用作抗溃疡剂和平滑肌松弛剂。
• A therapeutic agent for pollakiuria, urinary urgency or incontinence of urine comprising alpha-phenyl-alpha-pyridylalkanoic acid derivatives
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0452809A2

  公开（公告）日：1991-10-23

  A pharmaceutical composition as a therapeutic agent for dysuria comprising a compound of the formula : wherein R¹, R² and R³ are each lower alkyl, or its salt, as an active ingredient in association with a pharmaceutically acceptable, substantially nontoxic carrier or excipient.

  一种可用于治疗排尿困难的药物组合物，由式......化合物组成： 其中 R¹、R² 和 R³ 各为低级烷基，或其盐作为活性成分，与药学上可接受的、基本上无毒的载体或赋形剂一起使用。
• Oyasu Hitoshi, Nagano Masanobu, Akahane Atsushi, Tomoi Masaaki, Tada Tosh+, J. Med. Chem, 37 (1994) N 9, S 1378-1381
  作者：Oyasu Hitoshi, Nagano Masanobu, Akahane Atsushi, Tomoi Masaaki, Tada Tosh+

  DOI：——

  日期：——
• UEHDA, IKUO;NAGANO, MASANOBU;AKABA, ATSUSI
  作者：UEHDA, IKUO、NAGANO, MASANOBU、AKABA, ATSUSI

  DOI：——

  日期：——
• Alpha-aryl-alpha-pyridylalkanoic acid derivatives, process for preparation thereof and pharmaceutical composition comprising the same
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0105458B1

  公开（公告）日：1989-11-23